Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects (PRO-174/I)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03519516 |
|
Recruitment Status :
Completed
First Posted : May 9, 2018
Results First Posted : October 25, 2019
Last Update Posted : October 25, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Phase I clinical trial, to evaluate the safety and tolerability of the ophthalmic solution PRO-174 versus Sophixín Ofteno®, elaborated by Laboratorios Sophia, S.A. of C.V. on the ocular surface of ophthalmologically and clinically healthy subjects.
Goals:
To evaluate the safety and tolerability of the formulation PRO-174 manufactured by Laboratorios Sophia, S.A. of C.V. on the ocular surface of clinically healthy subjects.
Hypothesis:
The ophthalmic solution PRO-174 presents a safety and tolerability profile similar to the comparator in healthy subjects.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Conjunctivitis Conjunctivitis, Bacterial | Drug: PRO-174 Drug: Sophixín Ofteno® | Phase 1 |
Phase I clinical trial, to evaluate the safety and tolerability of the ophthalmic solution PRO-174 versus Sophixín Ofteno®, elaborated by Laboratorios Sophia, S.A. of C.V. on the ocular surface of ophthalmologically and clinically healthy subjects.
Goals:
Methodology:
Phase I clinical trial, controlled, of parallel groups, double blind, randomized, exploratory.
Number of patients:
30 subjects, divided into 2 groups [15 subjects (30 eyes) exposed per group]
Test product, dose and route of administration, lot number:
- PRO-174. Levofloxacin 0.5% ophthalmic solution. Prepared by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.
- Dosage: 1 drop every 2 hours during the waking period (8 daily applications), on day 1 and 2; continuing with 1 drop every 4 hours during the waking period (4 daily applications) from day 3 to 7. Both eyes.
- Route of administration: ophthalmic
Duration of treatment: 7 days
Statistical methodology:
The data will be expressed with measures of central tendency: mean and standard deviation for the quantitative variables. The qualitative variables will be presented in frequencies and percentages. The statistical analysis will be carried out through the Mann-Whitney U test for the quantitative variables for the difference between the groups. The intra-group difference will be made with the Wilcoxon rank test. The difference between the qualitative variables will be analyzed by means of X2 (Chi2). An alpha ≤ 0.05 will be considered significant.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 30 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Phase I clinical trial, controlled, of parallel groups, double blind, randomized, exploratory. |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Masking Description: | The blinding will correspond to the research subject and the principal investigator. In addition, the statistical analysis will be carried out in a blinded manner for the partial and final analysis. The masking will be done using boxes in the primary packaging identical in the two groups. Blinding for the research subject and the researcher will be done by replacing the commercial labels in the case of the comparator in the bottles and the use of identical labels that contain the allocation number. Blinding may be opened in the following cases:
|
| Primary Purpose: | Treatment |
| Official Title: | Phase I Clinical Trial, to Evaluate the Safety and Tolerability of the Ophthalmic Solution PRO-174 Versus Sophixín Ofteno®, Elaborated by Laboratorios Sophia on the Ocular Surface of Ophthalmological and Clinically Healthy Subjects |
| Actual Study Start Date : | January 25, 2018 |
| Actual Primary Completion Date : | May 25, 2018 |
| Actual Study Completion Date : | June 10, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: PRO-174
Active ingredient: Levofloxacin 0.5% o Dosage: 1 drop in both eyes, 8 times a day during the waking period |
Drug: PRO-174
Pharmaceutical form: ophthalmic solution
Other Names:
|
|
Active Comparator: Sophixín Ofteno®
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
|
Drug: Sophixín Ofteno®
Other Name: Ciprofloxacin Ophthalmic solution |
- Number of Adverse Events (EAS) [ Time Frame: during the 12 days of evaluation, including the safety call (day 12). ]primary security variable the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent.
- Ocular Burning (OB) [ Time Frame: will be evaluated at the end of the treatment at the final visit (day 7) ]
primary tolerability variable
Ocular burning is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:
Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.
- Intraocular Pressure (IOP) [ Time Frame: will be evaluated at the end of the treatment at the final visit (day 7) ]the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg
- Breakup Time (BUT) [ Time Frame: will be evaluated at the end of the treatment at the final visit (day 7) ]breakup time lacrimal film is a continuous variable that will be measured in seconds, evaluating the time it takes to break it, is done by direct counting and the normality range and mayor to 10 seconds.
- Number of Eyes With Epithelial Defects (ED) by Grade [ Time Frame: will be evaluated at the end of the treatment at the final visit (day 7) ]The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.
- Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade [ Time Frame: will be evaluated at the end of the treatment at the final visit (day 7) ]Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very Light / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.
- Number of Eyes With Foreign Body Sensation (FBS) by Grade [ Time Frame: will be evaluated at the end of the treatment at the final visit (day 7) ]
Foreign body sensation is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:
Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.
- Number of Eyes With Ocular Pruritus (P) by Grade [ Time Frame: will be evaluated at the end of the treatment at the final visit (day 7) ]
Ocular pruritus is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:
Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.
- Number of Eyes of Chemosis [ Time Frame: will be evaluated at the end of the treatment at the final visit (day 7) ]The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent.
- Visual Capacity [ Time Frame: will be evaluated at the end of the treatment at the final visit (day 7) ]
The visual capacity variable will be reported using as a unit of measure a fraction, this is taken from a visual test with the Snellen primer, it is a Nominal type variable. where the optimal vision is 20/20 and higher scores indicate worse visual acuity.
Snellen Scale: 20/200, 20/100, 20/70, 20/50, 20/40, 20/30, 20/25, 20/20, 20/15, 20/12, 20/10
only the denominator of the fraction of each case is reported and averaged per group.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Signed informed consent.
- Systemically and ophthalmologically healthy subjects evaluated during the clinical history.
- Age between 18 to 45 years.
- Both genders.
- Blood tests (complete blood count, blood chemistry of three elements and liver function tests) within normal parameters specified by the reference laboratory with a lower and upper margin of 10%.
- Vital signs within normal parameters. (Vital signs at rest: blood pressure ≤ 139/89 mmHg, heart rate 60 -100 beats per minute and respiratory rate of 12-24 breaths per minute).
- Visual capacity 20/30 or better, in both eyes.
- Intraocular pressure ≥11 and ≤ 21 mmHg.
Exclusion Criteria:
General criteria
- Subjects with a history of hypersensitivity to any of the components of the research products.
- Subject users of topical ophthalmic medications of any pharmacological group.
- Subject users of medication by any other route of administration.
- Pregnant or lactating women.
- Women of childbearing age, who do not ensure a hormonal contraceptive method or intrauterine device during the study period or without a history of bilateral tubal obstruction, oophorectomy or hysterectomy; as fertile age we understand women who have not had their menopause, defined as 12 months since the last menstruation in women over 40 years.
- Subjects with participation in clinical research studies 90 days prior to inclusion in the present study.
- Diagnosis of liver disease or elevation to three times the normal upper value of any of the following liver enzymes: aspartate transferase (AST), alanine transferase (ALT) or bilirubin.
- Inability to attend or answer the evaluations made in each of the visits.
- Positive smoking (specified as cigarette consumption regardless of amount and frequency)
- Positive alcoholism (specified as the consumption of alcoholic beverages, regardless of quantity and frequency, during the study intervention period).
- Contact lens users.
- An occlusive iridocorneal angle, defined as a trabecular mesh visible at less than 90 ° from the angular circumference to gonioscopy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03519516
| Mexico | |
| Private Medical Offices | |
| Guadalajara, Jalisco, Mexico, 44650 | |
| Study Director: | Leopoldo Baiza Durán, MD | Laboratorios Sophia S.A de C.V. |
Documents provided by Laboratorios Sophia S.A de C.V.:
| Responsible Party: | Laboratorios Sophia S.A de C.V. |
| ClinicalTrials.gov Identifier: | NCT03519516 |
| Other Study ID Numbers: |
SOPH174-0816/I |
| First Posted: | May 9, 2018 Key Record Dates |
| Results First Posted: | October 25, 2019 |
| Last Update Posted: | October 25, 2019 |
| Last Verified: | October 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
ocular antibiotic quinolone levofloxacin ophthalmic antibiotic antibiotic in drops |
|
Conjunctivitis, Bacterial Conjunctivitis Conjunctival Diseases Eye Diseases Eye Infections, Bacterial Bacterial Infections Bacterial Infections and Mycoses Infections Eye Infections Ciprofloxacin Levofloxacin Pharmaceutical Solutions |
Ophthalmic Solutions Anti-Bacterial Agents Anti-Infective Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 Enzyme Inhibitors Anti-Infective Agents, Urinary |